Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 4, July, p. 563–569

doi: 10.17219/acem/62536

PubMed ID: 28691424

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

An animal model of the procognitive properties of cysteine protease inhibitor and immunomodulatory peptides based on colostrum

Bartłomiej Stańczykiewicz1,A,B,C,D,F, Marta Jakubik-Witkowska1,B,C,D, Antoni Polanowski2,A,D,E, Tadeusz Trziszka2,A,F, Joanna Rymaszewska1,A,E,F

1 Division of Consultation Psychiatry and Neuroscience, Department of Psychiatry, Wroclaw Medical University, Poland

2 Department of Animal Products Technology and Quality Management, University of Environmental and Life Sciences, Wrocław, Poland


Background. The positive effect of human cystatin C on the development of Alzheimer’s disease has been reported, as it inhibits the formation of β-amyloid oligomers and amyloidogenesis. Cystatin C has been found to have a neuroprotective effect by inhibiting cysteine proteases, inducing autophagy and neurogenesis. There is a growing interest in the procognitive properties of colostrum-based specimens, which could delay dementia and ameliorate memory deterioration.
Objectives. The aim of the study was to evaluate the influence of ovocystatin and a Coloco peptide complex on the cognitive functions in reference to Colostrinin, using a model of young (4 month-old) and old (10-month-old) Wistar rats.
Material and Methods. In the present study, the effects of ovocystatin [100 μg/rat] and the Coloco peptide [4 μg/rat]derived from colostrum were assessed with respect to the reference specimen, Colostrinin [4 μg/rat]. The specimens were administered intraperitoneally and orally for 12 days. Cognitive functions were assessed using the Morris water maze (MWM).
Results. The group of young rats that received ovocystatin orally obtained significantly better results in the MWM compared to the placebo group (p < 0.05). Similarly, the group of young rats receiving Coloco orally obtained better results in the MWM compared to the placebo group and to the group of rats receiving Colostrinin (p < 0.05). There were no statistically significant differences in the oral and intraperitoneal administration of ovocystatin, Coloco and Colostrinin in the group of old rats.
Conclusion. The obtained results suggest that oral administration of ovocystatin and Coloco has beneficial effects on the cognitive functions of young rats.

Key words

ovocystatin, Coloco, Colostrinin (cln), Morris water maze, cognitive decline

References (30)

  1. Sosnowska A, Trziszka T, Polanowski A, Bubel F. Bioactive substances of hen eggs. Their biomedical importance and technological possibility for production in an industrial scale. Przem Chem. 2011;90(5):174–179.
  2. Rehault S. Antiproteases. In:. Huopalahti R, Lopez-Fandino R, Anton M, Schade R (eds.). Bioactive egg compounds. Berlin, Heidelberg: Springer Verlag. 2007:85–92.
  3. Warwas M, Piwowar A. Urinary cystatin C as a biomarker of renal tubular injury. Postepy Hig Med Dosw. 2011;65:562–568.
  4. Konopska B, Gburek J, Gołąb K, Warwas M. Influence of aminoglycoside antibiotics on chicken cystatin binding to renal brush-border membranes. J Pharm Pharmacol. 2013;65(7):988–994.
  5. Gołąb K, Gburek J, Juszczyńska K, Trziszka T, Polanowski A. Stabilization of monomeric chicken egg white cystatin. Przem Chem. 2012;91(5):741–744.
  6. Gauthier S, Kaur G, Mi W, Tizon B, Levy E. Protective mechanisms by cystatin C in neurodegenerative diseases. Front Biosci (Schol Ed). 2011;3:541–554.
  7. Kaur G, Levy E. Cystatin C in Alzheimer’s disease. Front Mol Neurosci. 2012;5:79.
  8. Levy E. Cystatin C. A potential target for Alzheimer’s treatment. Expert Rev Neurother. 2008;8(5):687–689.
  9. Sundelöf J, Arnlöv J, Ingelsson E, et al. Serum cystatin C and the risk of Alzheimer disease in elderly men. Neurology. 2008;71(14):1072–1079.
  10. Hansson SF, Andréasson U, Wall M, et al. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer’s disease patients. J Alzheimers Dis. 2009;16(2):389–397.
  11. Janusz M, Lisowski J, Franek F. Isolation and characterisation of a proline-rich polypeptide from ovine colostrum. FEBS Letters. 1974;49:276–279.
  12. Sokołowska A, Bednarz R, Pacewicz M, Georgiades JA, Wilusz T, Polanowski A. Colostrum from different mammalian species-A rich source of CLN. International Dairy Journal. 2008;18:204–209.
  13. Janusz M, Lisowski J. Proline – rich polypeptide (PRP) – an immunomodulatory peptide from ovine colostrum. Archivum Immunologiae et Therapiae Experimentalis. 1993;41;275–279.
  14. Zabłocka A, Janusz M, Macała J, Lisowski J. A proline-rich polypeptide complex (PRP) isolated from ovine colostrums. Modulation of H2O2 and cytokine induction in human leukocytes. International Immunopharmacology. 2007;7:981–988.
  15. Stewart MG. CLN: A naturally occurring compound derived from mammalian colostrum with efficacy in treatment of neurodegenerative diseases, including Alzheimer’s. Expert Opin Pharmacother. 2008;9(14):2553–2559.
  16. Georgiades JA, Polanowski A, Wilusz T, Kruzel ML. Purification of peptides from colostrm. 2007. Patent EP 1 613 648 B1.
  17. Kruzel ML, Polanowski A, Wilusz T, et al. The alcohol – induced conformational changes in casein micelles: A new challenge for the purification of Colostrinin. The Protein Journal. 2004;23:127–133.
  18. Polanowski A, Wilusz T, Dobrzyński W, Bodzicz S. Process for the preparation of peptide formulation. 2015. Patent PL nr 218693.
  19. Popik P, Bobula B, Janusz M, Lisowski J, Vetulani J. CLN, a polypeptide isolated from early milk, facilitates learning and memory in rats. Pharmacol Biochem Behav. 1999;64(1):183–189.
  20. Popik P. CLN and CLN-derived nonapeptide (colostral-val nonapeptide, CVNP) facilitate learning and memory in rats. Pol J Pharmacol. 2001;53(2):166–168.
  21. Leszek J, Inglot AD, Janusz M, Lisowski J, Krukowska K, Georgiades JA. CLN: A proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer’s disease. A double-blind, placebo-controlled study. Arch Immunol Ther Exp (Warsz). 1999;47(6):377–385.
  22. Leszek J, Inglot AD, Janusz M, et al. CLN proline-rich polypeptide complex from ovine colostrum--a long-term study of its efficacy in Alzheimer’s disease. Med Sci Monit. 2002;8(10):PI93-P196.
  23. Bilikiewicz A, Gaus W. CLN (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer’s disease. J Alzheimers Dis. 2004;6(1):17–26.
  24. Janusz M, Woszczyna M, Lisowski M, et al. Ovine colostrum nonapeptide affects amyloid beta aggregation. FEBS Lett. 2009;583(1):190–196.
  25. Gołąb K, Gburek J, Juszczyńska K, Trziszka T, Polanowski A. Stabilization of monomeric chicken egg white cystain. Przem Chem. 2012;91:741–744.
  26. Gołąb K, Horowski A, Warwas M. Chicken cystatin as a model protein in medical science. Farm Pol. 2008;64(17):759–769.
  27. Nagai A, Ryu JK, Terashima M, et al. Neuronal cell death induced by cystatin C in vivo and in cultured human CNS neurons is inhibited with cathepsin B. Brain Res. 2005;1066(1–2):120–128.
  28. Kaeser SA, Herzig MC, Coomaraswamy J, et al. Cystatin C modulates cerebral beta-amyloidosis. Nat Genet. 2007;39(12):1437–1439.
  29. Mi W, Pawlik M, Sastre M, et al. Cystatin C inhibits amyloid-beta deposition in Alzheimer’s disease mouse models. Nat Genet. 2007;39(12):1440–1442.
  30. Sun B, Zhou Y, Halabisky B, et al. Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer’s disease. Neuron. 2008;60(2):